Lead strategic operations across Science in Society, focusing on grants programs development and operations, and team practices. Provide key leadership for strategic explorations and special projects. Lead the team responsible for grounding our work in equity and understanding the operation of the policy landscape in which programs are situated. Advance cross-cutting activities at the intersection of equity, inclusion, community, and collaboration.

Drive strategy development and execution of Science in Society core initiatives at the intersection of health sciences, policy, and ethics. Serve as a key lead in setting the strategic direction and priorities of the Science in Society program.Manage grants program development, including a grants portfolio to boost capacity of the scientific enterprise for engaging ethically, equitably, and effectively with communities, civic society, and policy makers.Coordinate cross-functional efforts that aim to advance equity, diversity, and inclusion and capacity for community engagement among scientists. Lead CZI Science Diversity, Equity, and Inclusion and Racial Equity priority initiatives. Member of the CZI Racial Equity Working Group and the CZI Inclusion, Diversity, Equity, and Accessibility Working Group.

Provided leadership and senior management regarding complex health sciences policy issues with particular focus on therapeutics discovery and development, clinical research, and ethics of health science including emerging biotechnology. Fostered in-depth exploration of complex issues and built broad networks. Forged connections, provided strategic advice, and curated priorities. Developed, oversaw, convened, and evaluated activities. Awarded the Einstein Award (Nov 2015), which was given to the IOM staff member who is recognized as an “innovative thinker”. The recipient of this award develops innovations in procedures, is resourceful and imaginative, and has a forward-looking vision for the Institute of Medicine.In addition to the programs I directed that are listed below, over the course of my tenure at the IOM I also served as a Senior Advisor and Project Developer for the following activities:- Returning Individual Research Results to Participants: Guidance for a New Research Paradigm (2018)- Workshop on Physician-Assisted Death: Scanning the Landscape (2018)- Integrating Clinical Research into Epidemic Response: The Ebola Experience (2017)- Ensuring Safe Foods and Medical Products Through Stronger Regulatory Systems Abroad (2012)

The Forum on Drug Discovery, Development, and Translation provides a unique platform for dialogue and collaboration among thought leaders in government, academia, industry, foundations, and disease and patient advocacy. The Forum serves as a hub and a catalyst for nurturing new ideas and partnerships and offers a neutral space for stakeholders to advance critical policy discussions on biopharmaceutical innovation nationally and globally. As Director, I oversaw a team of four staff to convene Forum membership (including C-suite biopharma executives, federal regulatory and research agency institute and center directors, and distinguished research scientists); develop and execute international workshops; and catalyze partnerships and policy to advance therapeutics discovery and development.Publications included:- Real-World Evidence Generation and Evaluation of Therapeutics (2017)- Advancing the Discipline of Regulatory Science for Medical Product Development: An Update on Progress and a Forward-Looking Agenda (2016)- Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products (2014)- Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network (2012)- Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 (2012)- Advancing Regulatory Science for Medical Countermeasure Development (2011)- Building a National Framework for the Establishment of Regulatory Science for Drug Development (2010)

Mitochondrial replacement techniques (MRT) are designed to prevent the transmission of mitochondrial DNA (mtDNA) diseases from mother to child. The goal of MRT is to prevent the transmission of these serious diseases by creating an embryo with nuclear DNA (nDNA) from the intended mother and mtDNA from a woman with nonpathogenic mtDNA through modification of either an egg or zygote. While MRT, if effective, could satisfy the desire of women seeking to have a genetically related child without the risk of passing on mtDNA disease, the techniques raise ethical, social, and policy issues. As Study Director, I convened, at the request of the Food and Drug Administration, a distinguished 12-person expert committee with diverse interdisciplinary expertise and a range of backgrounds to examine and analyze these issues, make recommendations regarding whether and how to go forward with MRT, and elaborate principles for initial clinical investigations involving these novel techniques for avoiding some types of inherited mtDNA diseases.

Outbreaks of emerging infectious diseases in the 21st century, starting with severe acute respiratory syndrome (SARS) in 2003 and including the 2014 reemergence of Ebola virus disease, demonstrate that the international community does not have adequate systems in place to reliably prepare for, detect, and rapidly respond to large-scale public health emergencies. With encouragement and input from the World Bank; the World Health Organization (WHO); and the governments of the United Kingdom, United States, and West African countries; and support from various international and national organizations, the National Academy of Medicine managed an international, independent, evidence-based, authoritative, multistakeholder expert Commission on improving international management and response to outbreaks. As part of this effort, the Institute of Medicine (IOM) convened four workshops in the summer of 2015 to inform the Commission report. These workshops examined questions of governance for global health, pandemic financing, resilient health systems, and research and development of medical products. As Director of the workshop on research and development of medical products, I oversaw a team of four IOM staff to develop and convene, in consultation with a distinguished planning committee, an international workshop held in Hong Kong in August 2015. The workshop, which was headlined by the Director General of the WHO, considered strategies, systems, and policies needed to foster communication and create partnerships to advance the development of vaccines, diagnostics, therapeutics, and personal protective equipment (PPE) for emerging infectious diseases.For this work, I was one of a group of IOM staff to be honored with the IOM "Team Award," awarded to the unit or project team that has worked exceptionally well together to achieve a set of goals. The recipients of this award prioritize the success of the group over the individual success of any one team member.

Data sharing can have important benefits, including accelerating medical innovation by reducing redundancies, facilitating the identification and validation of new drug targets, identifying new indications for use, and improving understanding of the safety and efficacy of therapies. In 2013, a group of federal, industry, and U.S. and international foundation sponsors asked the IOM to conduct a consensus study that would generate guiding principles and a framework for the responsible sharing of clinical trial data. The IOM convened a 13-member expert committee that produced a report outlining guiding principles and recommendations for best practices for clinical trial data sharing. As responsible staff officer, I developed the scope of work, assembled the expert committee, oversaw the IOM staff executing the study, and advised the committee and IOM staff on the report content.

The burden of drug-resistant tuberculosis introduces new challenges to traditional TB control and treatment programs, and calls upon the global health community to collaborate in new and different ways. From 2008 to 2013, the IOM convened six public workshops on the science and policy surrounding drug-resistant tuberculosis. The workshops took place in Washington, DC; Pretoria, South Africa; Moscow, Russia; New Delhi, India; and Beijing, China. Issues covered at the workshops ranged from biology, epidemiology, and surveillance to diagnosis, treatment, and infection control as well as the drug supply chain and needs of vulnerable populations. Publications:- Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis (2013) (Wash DC)- The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities (2013) (Beijing)- Facing the Reality of Drug-Resistant Tuberculosis in India: Challenges and Potential Solutions (2012) (New Delhi)- The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective (2011) (Moscow)- The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions (2011) (Pretoria)

Associate practicing in the Health Care Group, with an emphasis on health care regulatory matters. Advised academic medical centers and research hospitals, large pharmaceutical companies, physician organizations, dialysis companies, and health care purchasers and payers. Particular substantive expertise in:• Health care regulatory compliance• Financing, conduct, and ethical/regulatory oversight of international public health and research projects• Structuring of novel research collaborations and business ventures (e.g., tissue/data sharing consortium; life sciences venture spin-outs)• Conflicts of interest in health care research and treatment• Health care organization, delivery, and financing reform• Health care antitrust• Federal grants compliance

Provided research support for all aspects of a multi-site, longitudinal health services research project studying strategies and effectiveness of implementing adolescent clinical preventive services in pediatric managed care settings. Responsibilities included human subjects research compliance, statistical analysis, and development of research instruments and intervention. Developed and evaluated training programs for health educators and physicians. Served as primary support for oversight of personnel (site research team of six) and administrative aspects of project.

Advised nonprofit health care organizations delivering health care services to adolescents on policy, advocacy, and strategy. Researched and prepared health policy and needs assessment reports on behalf of a cross-functional coalition. Served as a catalyst and co-convener of the San Francisco Adolescent Health Working Group.